Company: ANIX
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012701
Chunk: 12

Company: Anixa Biosciences Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 12
---
 proceeds of approximately $4,000 and $7,000, respectively .

Warrants

As of April 30, 2025, we had warrants
outstanding to purchase 300,000 shares of common stock at $6.56 per share, issued during fiscal year 2021 and expiring on March 22, 2026.

Information regarding the Company’s
warrants for the six months ended April 30, 2025 is as follows:

 SCHEDULE
OF WARRANTS ACTIVITY

    Shares  
    Weighted  Average
                                                                               Exercise  Price Per Share  
    Aggregate  Intrinsic  Value 
  
    Warrants outstanding at October 31, 2024 
     300,000  
    $6.56  

    Warrants outstanding and exercisable at April 30, 2025 
     300,000  
    $6.56  
    $0 

The following table summarizes
information about the Company’s outstanding and exercisable warrants as of April 30, 2025:

 SCHEDULE
OF OUTSTANDING AND EXERCISABLE WARRANTS

    Range of Exercise Prices  
    Number Outstanding and Exercisable  
    Weighted Average Remaining Contractual Life (in years)  
    Weighted Average Exercise Price 
  
    $6.56  
     300,000  
     0.9  
    $6.56 

Stock Awards

During the three and six months
ended April 30, 2025, we did not issue any stock awards. During the three and six months ended April 30, 2024, we issued 29,336 shares
and 29,336 shares of common stock, respectively, to consultants providing investor relations services, and recorded expense of approximately
$96,000 and $96,000, respectively.

    12

Treasury stock

During the fiscal year
ended October 31, 2024, the Company purchased 2,000
shares of its common stock as treasury stock. The shares were purchased at an average cost of $3.17
per share for a total cost of approximately $6,000.
The repurchases were made as part of a stock buyback program approved by our Board of Directors on July 11, 2024. The treasury
shares were accounted for under the cost method and were recorded as a reduction in shareholders’ equity in the condensed
consolidated balance sheet